Abivax shares sink after key trial results for inflammatory bowel drug
By Gianluca Lo Nostro June 2 (Reuters) – Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment showed strong efficacy. The shares were down 30% in early Paris trading, leading losses on Europe’s STOXX 600 benchmark index, after a spectacular rally last year that saw the stock rise more than 16-fold. […]